Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement
Simona Soverini(University of Bologna), Giovanni Martinelli(University of Bologna), Mario Luppi(University of Modena and Reggio Emilia), Marzia Salvucci(Ospedale "Santa Maria delle Croci" di Ravenna), Gian Matteo Rigolin, Domenico Russo(University of Brescia), Caterina De Benedittis(University of Bologna), Michele Baccarani(University of Bologna), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Fabrizio Pane(Federico II University Hospital), Ilaria Iacobucci(St. Jude Children's Research Hospital), Paola Bresciani(Azienda Ospedaliero-Universitaria di Modena), Massimiliano Bonifacio(University of Verona), Simona Sica(San Antonio College), Tamara Intermesoli(University of Bergamo), Michèle Cavo(Unknown), Ester Orlandi(University of Pavia), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Claudia Venturi(University of Bologna), Antonella Gozzini(Azienda Ospedaliero-Universitaria Careggi)
Cited by 143
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k